
Dr Aidan Murphy becomes Ipsen’s new Executive VP, Technical Operations
pharmafile | January 10, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | appointment, ipsen, pharma
Dr Aidan Murphy has been named by Ipsen’s new Executive Vice President, Technical Operations, succeeding Jonathan Barnsley who retired at the end of 2017. In addition to his new position, Dr Murphy will also serve on the French biopharmaceutical company’s executive leadership team.
Dr Murphy has worked in the pharmaceutical and biotechnology industry for more than 25 years, and has served at Ipsen since 2007, boasting a range of manufacturing leadership roles across a number of countries throughout his career. Dr Murphy has held the role of Senior Vice President, Biologics Development and Manufacturing at Ipsen since 2014, and has previously led manufacturing sites in Tianjin in China, Dublin in Ireland, and Wrexham in England during his time with the company.
David Meek, CEO of Ipsen, commented on Dr Murphy’s appointment, remarking: “It is my great pleasure to welcome Aidan to Ipsen’s executive leadership team. He brings outstanding manufacturing leadership experience and an international perspective, having worked across multiple geographies both prior to and during his career with Ipsen. Aidan has played an instrumental role in the transformation of Ipsen Technical Operations in recent years, and the continuity of leadership he brings will be critical as we continue our development as a leading global biopharma company.”
Related Content

Phase 3 trials support expanded use of Dysport for migraine prevention
Ipsen has reported positive topline results from its phase 3 BEOND clinical programme evaluating Dysport …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …






